



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/827,369
Applicant : Baldomero M. OLIVERA et al.
Filed : 20 April 2004
TC/A.U. : 1653
Examiner : Rosanne KOSSON

Confirmation No.: 4193

Attorney Docket No. : 2314-278
Customer No. : 6449

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:


In the Office Action mailed 7 July 2006, the Examiner required restriction between 19 Groups. In response thereto, Applicants herewith elect Group I, claims 1-3 and 9-15 directed to a method for treating a cardiovascular disorder. Applicants further elect the sequence of SEQ ID NO:1. This election is made without traverse.

In introductory comments to the restriction, the Examiner asserted that SEQ ID NO:1 did not read on all of the peptides set forth in the claims. However, Applicants note that the Examiner is incorrect in this assertion because several of the residues in SEQ ID NO:1 can be lacking (e.g., Xaa₁ can be des-Xaa₁). Thus, SEQ ID NO:1 reads on all of the peptides set forth in the claims.

Respectfully submitted,

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

By


Jeffrey L. Ihnen, Reg. No. 28,957
Attorney for Applicants
1425 K Street, N.W., Suite 800
Washington, D.C. 20005
Telephone No.: (202) 783-6040
Facsimile No.: (202) 783-6031